Lei Lei Wu

Pancreatic cancer patients with the most common KRAS mutation appeared to have a lower response rate than the overall patient population with Revolution Medicines’ Rasonque.

BioNTech’s mRNA vaccine BNT113 misses PFS goal in a Phase 2/3 head and neck cancer trial; the study continues toward its overall survival endpoint.

Gilead pays Vir Biotechnology $65M upfront plus $25M investment for 3 T cell engager solid tumor therapies. Deal includes $1.79B in potential milestones. Vir shares up 78% YTD.

Verastem Oncology announced VS-7375 data showing 41% response rate in pancreatic cancer, raised $250M, and CEO Dan Paterson stepping down, replaced by Michael Bailey.

More former Genentech leaders are finding a new home. Lélia Delamarre posted on LinkedIn that she’s leading R&D at ARCH-backed cancer biotech Medici Therapeutics, one of this year’s Endpoints 11 winners.

Novartis terminated a mid-stage trial of Fabhalta in lupus nephritis, citing “strategic considerations,” according to a federal clinical trials database.

Disc Medicine's bitopertin met all Phase 3 APOLLO endpoints for EPP, showing 12.2 more pain-free light hours and 41.4% PPIX reduction vs placebo.

Bristol Myers Squibb MS patient died post zola-cel CAR-T treatment from septic pneumonia. Company links prior ICANS cases to manufacturing reagent changes, plans trial restart early 2025.

Bristol Myers’ cell therapy chief Lynelle Hoch explains the reagent behind its autoimmune CAR-T pause and a puzzling MS trial death.

LANCASTER, PA — This spring, Lorraine and Mark Martin, a Mennonite family with a tax business, adopted a stubby-legged cow named Royal Lite.